Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN1908-1909 · 3 trials · 3 indications
Time to EAR was defined as the time to a ≥20% reduction in FEV1 or when the participant voluntarily departed the EEU due to clinically significant allergic and/or asthmatic symptoms.
The primary endpoint is the change in allergic symptom scale score at day 8
The primary endpoint is to assess treatment-emergent adverse events (TEAEs) from day 1 through day 113 (end of study).
| Arm | Type | Description |
|---|---|---|
| REGN1908-1909 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Group A | EXPERIMENTAL | Participants in group A will receive REGN1908-1909 |
| Group B | EXPERIMENTAL | Participants in group B will receive placebo |
| Cohort 1 | EXPERIMENTAL | Dose 1 of REGN1908-1909 or placebo |
| Cohort 2 | EXPERIMENTAL | Dose 2 of REGN1908-1909 or placebo |
| Cohort 3 | EXPERIMENTAL | Dose 3 of REGN1908-1909 or placebo |
| Name | Type | Description |
|---|---|---|
| REGN1908-1909 | DRUG | Single subcutaneous (SC) dose of REGN1908 and REGN1909 |
| Placebo | DRUG | Single subcutaneous (SC) dose of matching placebo |
Key Inclusion Criteria: * Documented or patient reported history (for at least 2 years) of symptomatic cat allergen-triggered asthma with rhinitis with or without conjunctivitis * No cat exposure at home for the past year and must continue having no exposure at home during the study; cat exposure o...
REGN1908-1909 is being developed for allergy, specifically cat allergy. It is designed to reduce allergic responses in people sensitized to cat allergen. Clinical studies have also evaluated it in patients with cat allergy and mild asthma to reduce bronchoconstriction after cat allergen challenge.
REGN1908-1909 targets FelD1, the major cat allergen protein. By binding FelD1, the drug is intended to block the allergen from triggering allergic reactions in sensitized individuals. This targeted approach distinguishes it from symptomatic allergy treatments that act downstream of allergen exposure.
REGN1908-1909 is being developed by Regeneron Pharmaceuticals, Inc., which trades on Nasdaq under the ticker REGN. Regeneron is the sponsor of the clinical trials evaluating this asset in allergic patients.
REGN1908-1909 is in Phase 1 development. It is an investigational small molecule and has not been approved by the FDA. The completed trials include Phase 1 and Phase 2 studies, but the asset remains in clinical development.
REGN1908-1909 has been studied in three completed trials: NCT03838731, a Phase 2 study in cat-allergic patients with mild asthma in France; NCT02127801, a Phase 1 study in allergic adults across the Netherlands, New Zealand, Sweden, and the United Kingdom; and NCT01922661, a Phase 1 study in allergic adults in the United States.